Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267699 | 0.89 | KMT2A (0.60) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL6407780 | 0.86 | KMT2A (0.56) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL1534196 | 0.84 | TP53 (0.64) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL28422775 | 0.81 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL2098193 | 0.81 | ALDH1A1 (0.59) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL2098194 | 0.81 | ALDH1A1 (0.59) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL16922181 | 0.81 | NPC1 (0.66) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL1039601 | 0.81 | KMT2A (0.76) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL7888049 | 0.81 | CYP1A1 (0.60) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL1503954 | 0.81 | NPC1 (0.66) | KMT2AMEN1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | claimed |
| JP-6299097-A | — | — | None | — | — | JP | disclosed |
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| CN-118459362-A | N-aryl-2- (2-hydroxybenzyloxy) acetamides, preparation method and application thereof | 湖南科技大学 | 2024-08-09 | — | — | CN | disclosed |
| US-20240034727-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. | 2024-02-01 | — | — | US | disclosed |
| CN-117003744-A | Five-membered and six-membered compound, intermediate, preparation method, composition and application | 厦门市博瑞来医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116963733-A | Imidazole compounds as ENPP1 inhibitors | 斯汀格瑞治疗股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4255425-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-114409657-B | 4-aryl (methyl) imidazoline quinoxalinone compound and preparation method and application thereof | 湖南科技大学 | 2023-02-24 | — | — | CN | disclosed |
| EP-1426364-A1 | Imidazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| JP-2000198771-A | PHENYLPYRROLIDINONE DERIVATIVE | EISAI CO LTD | 2000-07-18 | — | — | JP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| JP-H06299097-A | ANTIFOULING COATING COMPOSITION | ISHIHARA SANGYO KAISHA LTD | 1994-10-25 | — | — | JP | disclosed |
| EP-0140271-A2 | Iodoacetamides | BAYER AG (DE) | 1985-05-08 | — | — | EP | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | KMT2A 1544/4885MEN1 1968/4885SMN1; SMN2 4241/4885 |
| US-20240034727-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | ENPP1, PPP1R1B, PPM1B | KMT2A 2718/4885MEN1 231/4885SMN1; SMN2 865/4885 |
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | WRN, RECQL, BLM | KMT2A 1697/4885MEN1 1859/4885SMN1; SMN2 2576/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | KMT2A 1093/4885MEN1 1167/4885SMN1; SMN2 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.